Long-Term Risdiplam for Spinal Muscular Atrophy
(WeSMA Trial)
Trial Summary
What is the purpose of this trial?
A multi-center, longitudinal, prospective, non-comparative study to investigate the long-term safety and effectiveness of risdiplam, prescribed based on clinician judgment as per the Evrysdi® U.S. Package Insert (USPI) in adult and pediatric participants with SMA. In this study, participants will be followed for the duration of the study or until withdrawal of consent, loss to follow-up, or death. Participants who discontinue risdiplam may still remain in the study, if they agree to continue participating in the follow-up assessments. An optional sub study will assess the feasibility, acceptability, and adherence of remote assessment of motor and bulbar functions in participants with SMA using wearable and smartphone-based biosensors. Approximately 39 participants from the main study are planned to be enrolled in the sub study.
Do I have to stop taking my current medications for this trial?
The trial protocol does not specify whether you need to stop taking your current medications. It is best to discuss this with your doctor.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It seems that you can continue taking risdiplam if prescribed, but it's best to discuss your specific situation with the trial team or your doctor.
What data supports the idea that Long-Term Risdiplam for Spinal Muscular Atrophy is an effective drug?
The available research shows that Risdiplam significantly improves motor function in patients with Spinal Muscular Atrophy (SMA). In clinical trials, infants with SMA type 1 and patients aged 2-25 years with SMA types 2 or 3 showed improved motor skills after using Risdiplam. These improvements were maintained for up to two years. Additionally, a systematic review found that after 12 months of treatment, 57% of participants with SMA type 1 achieved better motor function, and those with SMA types 2/3 also showed improvements. Risdiplam is generally well tolerated, making it a convenient and effective option for a wide range of patients.12345
What data supports the effectiveness of the drug Risdiplam for treating spinal muscular atrophy?
Risdiplam has been shown to significantly improve motor function in patients with spinal muscular atrophy, including infants with type 1 and patients aged 2-25 years with types 2 or 3. These improvements were maintained for up to 2 years, and the drug is generally well tolerated, providing a convenient oral treatment option.12345
What safety data is available for Risdiplam in treating spinal muscular atrophy?
Risdiplam, also known as Evrysdi, has been evaluated for safety in several studies. It is generally well tolerated with a favorable benefit-risk balance. In phase 2/3 clinical trials, it showed significant improvements in motor function for SMA patients and was well tolerated over up to 2 years of treatment. A systematic review and meta-analysis found that 16% of participants experienced adverse events, though serious adverse events were not quantified due to a lack of cases. Overall, the available evidence suggests that Risdiplam is a safe and effective treatment for SMA.12346
Is Risdiplam generally safe for humans?
Is the drug Risdiplam a promising treatment for Spinal Muscular Atrophy?
Yes, Risdiplam is a promising drug for Spinal Muscular Atrophy. It is the first oral medication approved to treat this condition and has shown significant improvements in motor function for patients. It works by increasing the production of a crucial protein that patients with this disease lack. Risdiplam is convenient to use and has been approved for a wide range of ages and types of the disease.12356
How is the drug Risdiplam unique in treating spinal muscular atrophy?
Risdiplam is unique because it is the first oral drug for spinal muscular atrophy, making it more convenient than other treatments that require injections. It works by modifying the SMN2 gene to increase the production of a protein essential for muscle function, which is lacking in people with this condition.12356
Research Team
Clinical Trials
Principal Investigator
Hoffmann-La Roche
Eligibility Criteria
This trial is for both adults and children with a confirmed diagnosis of 5q-autosomal recessive Spinal Muscular Atrophy (SMA). Participants must be prescribed risdiplam based on their doctor's judgment. Those allergic to risdiplam or who were in previous registrational trials for the drug cannot join.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive risdiplam treatment as prescribed based on clinician judgment
Follow-up
Participants are monitored for safety and effectiveness after treatment
Substudy
Remote assessment of motor and bulbar functions using wearable and smartphone-based biosensors
Treatment Details
Interventions
- Risdiplam
Risdiplam is already approved in United States, European Union, Brazil, China for the following indications:
- Spinal muscular atrophy (SMA) in patients 2 months of age and older
- 5q-autosomal recessive SMA with a clinical diagnosis of SMA types 1, 2, or 3 or with one to four survival motor neuron 2 (SMN2) copies
- Spinal muscular atrophy (SMA)
- Spinal muscular atrophy (SMA)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Genentech, Inc.
Lead Sponsor
Ashley Magargee
Genentech, Inc.
Chief Executive Officer since 2024
MBA from Harvard University, BA from Princeton University
Levi Garraway
Genentech, Inc.
Chief Medical Officer since 2021
MD, PhD